AI
Apnimed, Inc.
SEC filingPharmaceuticals · Cambridge, MA
Amount raised$25Msold at filing
Total offering$25M
Investors in the raise2count reported to the SEC
FiledMar 27, 2026first sale Mar 11, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Lawrence G. MillerExecutive Officer, Director
Paul C. FonteyneDirector
Dennis G. MolnarExecutive Officer
Barry G. WohlExecutive Officer
Joseph C. AvelloneDirector
Francois C. BeaubienDirector
Chris C. DimitropoulosDirector
Kevin C. LindDirector
Isaac C. ChengDirector
Gary C. SenderDirector
Ramzi C. BenamarExecutive Officer
Executive officers, directors and promoters as listed on the Form D.